News for Acacia Pharma Group plc (0PNT.L)

The need for antiemetic drugs, which help prevent or relieve nausea and vomiting, is growing for several reasons. A key factor is the rising incidence of...

• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1 •...

/PRNewswire/ -- The Cancer Supportive Care Market by Therapeutic Area, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been...

WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the...

Q3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share1Total...

WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the...

Read Acacia Pharma Group plc (OTCMKTS:ACPGF) Short Interest Down 52.7% in June at ETF Daily News

Read Acacia Pharma Group plc (OTCMKTS:ACPGF) Short Interest Update at ETF Daily News

Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protectionBARHEMSYS® (amisulpride for injection) and...